This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed Balance Sheet Health

Financial Health criteria checks 6/6

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-62.2x
CashUS$820.37m
EquityUS$1.54b
Total liabilitiesUS$156.76m
Total assetsUS$1.70b

Recent financial health updates

Recent updates

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Oct 24
Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed's Impella low profile sheath gets FDA clearance

Oct 17

Abiomed: Correction Offers Good Buying Opportunity

Sep 28

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Sep 16

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Sep 13
What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed FQ1 2023 Earnings Preview

Aug 03

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Jul 11
Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

May 17

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Mar 17
Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Jan 24

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

Jan 04
The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Dec 14
These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed: Impella Will Continue To Drive Revenue Growth

Sep 10

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Sep 01
Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Jul 13

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Jul 08
At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Jun 08

Abiomed acquires preCARDIA a company targeting acute heart failure

Jun 01

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

May 16
Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

May 06

Abiomed FQ4 2021 Earnings Preview

Apr 28

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Apr 02
Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 12
Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?

Feb 18
Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?

Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Jan 31
Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Financial Position Analysis

Short Term Liabilities: ABMD's short term assets ($1.1B) exceed its short term liabilities ($134.1M).

Long Term Liabilities: ABMD's short term assets ($1.1B) exceed its long term liabilities ($22.7M).


Debt to Equity History and Analysis

Debt Level: ABMD is debt free.

Reducing Debt: ABMD had no debt 5 years ago.

Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.